Re-evaluating Age Stratification in AML: Evidence from Molecular and Clinical Data

Article Impact Level: HIGH
Data Quality: STRONG
Summary of Leukemia, https://doi.org/10.1038/s41375-025-02644-0 
Dr. Monica Cusan  et al.

Points

AML patient outcomes worsen with age, often leading to routine “younger” versus “older” age dichotomization.
This study analyzed 2823 AML patients from USA and Germany to assess age-related molecular and outcome trends.
Mutational profiles and cytogenetic abnormality distributions were similar across cohorts, consistently associating with age.
Overall survival linearly shortened with increasing age (P < 0.001), persisting across all ELN genetic-risk groups.
No distinct age cut-off was found, supporting greater age-associated flexibility for drug approval and trial eligibility.

Summary

This multi-dimensional analysis investigated age-associated trends in the mutational landscape and treatment outcomes of acute myeloid leukemia (AML), aiming to determine if conventional age-based patient stratification (e.g., “younger” versus “older”) is supported by molecular genetic features and clinical outcomes. The study analyzed 2823 adult AML patients from frontline chemotherapy-based clinical protocols of two cooperative study groups in the USA and Germany. Patients were molecularly profiled using targeted sequencing platforms to depict frequencies of gene mutations and cytogenetic findings in 5-year age increments. Clinical outcomes of 2756 AML patients were subsequently analyzed in relation to molecular features, genetic-risk groups, and age.

The findings revealed that age-associated distributions of gene mutations and cytogenetic abnormalities were similar across both cohorts. A critical observation was the almost linear shortening of overall survival (OS) with increasing age among all patients (P < 0.001). This inverse relationship between age and survival persisted even within the 2022 European LeukemiaNet (ELN)-defined genetic-risk groups, where survival consistently decreased as age increased (favorable-risk, P < 0.001; intermediate-risk, P < 0.001; adverse-risk, P < 0.001). This robust statistical evidence underscores the pervasive influence of age on AML prognosis across different genetic risk categories.

While the mutational profiles and outcomes of the very youngest patients differed distinctly from those of older individuals, the analysis did not identify any single, definitive age cut-off that could clearly dichotomize “younger” and “older” patient populations. This lack of a clear molecular or outcome-driven age threshold challenges the routine clinical practice of rigid age-based classifications. The study’s conclusions advocate for greater age-associated flexibility in drug approval processes and clinical trial eligibility criteria, suggesting a more nuanced approach to AML patient management beyond traditional age dichotomies.

Link to the article: https://www.nature.com/articles/s41375-025-02644-0

References

Cusan, M., Larkin, K., Nicolet, D., Jurinovic, V., Mrózek, K., Batcha, A. M. N., Rothenberg-Thurley, M., Schneider, S., Sauerland, C., Görlich, D., Krug, U., Berdel, W. E., Woermann, B. J., Hiddemann, W., Braess, J., Spiekermann, K., Greif, P. A., Blachly, J. S., Mims, A. S., … Eisfeld, A.-K. (2025). Multi-dimensional analysis of adult acute myeloid leukemia cross-continents reveals age-associated trends in mutational landscape and treatment outcomes (Acute myeloid leukemia cooperative group & alliance for clinical trials in oncology). Leukemia, 1–9. https://doi.org/10.1038/s41375-025-02644-0